A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- 01 Oct 2019 Planned End Date changed from 1 Aug 2019 to 1 Mar 2020.
- 01 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Jan 2020.
- 01 Oct 2019 Status changed from recruiting to active, no longer recruiting.